BioCentury
ARTICLE | Clinical News

InFuse Bone Graft: Postmarketing study data

June 24, 2013 7:00 AM UTC

Data from a pair of independent, systematic reviews analyzing the safety and efficacy of Medtronic's InFuse Bone Graft were published in the Annals of Internal Medicine. In 2011, Medtronic commissioned Yale University to review the safety and efficacy of InFuse following reports published in The Spine Journal in June 2011 alleging that the company failed to disclose financial ties to medical researchers involved in InFuse trials. The reports also claimed those same researchers failed to report the risk of complications associated with InFuse (see BioCentury, Aug. 8, 2011). Yale subsequently commissioned a panel of researchers from Oregon Health & Sciences University and the University of York to conduct separate analyses. ...